[1]CurrentPatentAssignee:KATHOLIEKEUNIVERSITEITLEUVEN-US2008/199427,2008,A1Locationinpatent:Page/Pagecolumn8-9
[2]CurrentPatentAssignee:KATHOLIEKEUNIVERSITEITLEUVEN-US2009/36460,2009,A1Locationinpatent:Page/Pagecolumn9;10
[1]Patent:US2008/199427,2008,A1.Locationinpatent:Page/Pagecolumn6-7
[2]Patent:WO2013/40492,2013,A2.Locationinpatent:Page/Pagecolumn58-59
[1]Patent:US2011/306541,2011,A1
Title: Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug.
Journal: Antimicrobial agents and chemotherapy 20140401
Title: Imidazopyridazine hepatitis C virus polymerase inhibitors. Structure-activity relationship studies and the discovery of a novel, traceless prodrug mechanism.
Journal: Journal of medicinal chemistry 20140313
Title: Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451.
Journal: Antimicrobial agents and chemotherapy 20140201
Title: In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
Journal: Antiviral research 20131101
Title: Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a.
Journal: Virology 20120720
Title: Integrated structure-based activity prediction model of benzothiadiazines on various genotypes of HCV NS5b polymerase (1a, 1b and 4) and its application in the discovery of new derivatives.
Journal: Bioorganic & medicinal chemistry 20120401
Title: The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function.
Journal: PloS one 20120101
Title: Bae AS, et al. Allele-specific real-time PCR system for detection of subpopulations of genotype 1a and 1b hepatitis C NS5B Y448H mutant viruses in clinical samples. J Clin Microbiol. 2011 Sep;49(9):3168-74.
Title: Hebner CM, et al. The HCV non-nucleoside inhibitor Tegobuvir utilizes a novel mechanism of action to inhibit NS5B polymerase function.PLoS One. 2012;7(6):e39163.
Title: Wong KA, et al. Tegobuvir (GS-9190) potency against HCV chimeric replicons derived from consensus NS5B sequences from genotypes 2b, 3a, 4a, 5a, and 6a. Virology. 2012 Jul 20;429(1):57-62.
